Stay updated with breaking news from Early Access Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early deathFiling for Early Access Programs to Sarconeos (BIO101) is being initated while preparing
Biophytis / Key word(s): Miscellaneous Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO1...
Biophytis / Key word(s): Miscellaneous Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 02-Feb-2023 / 08:00 CET/CEST Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 C...
Daniel Gallo, Ph.D., Appointed Senior Vice President of Medical Affairs and Advocacy Abbi Maher, J.D., Named Vice President of Legal Affairs CELEBRATION, Fla., Jan. 31, 2023 -- KemPharm, Inc. ,... | January 31, 2023
HOLOPLOT, a science-based immersive audio company, will exhibit at ISE 2023, which takes place in Barcelona from 31 January to 3 February